通过IKBKB介导的NF-κB信号通路激活,CircACTR2促进了膀癌的进展
Ping Li1, Zhang Zhao2, Qichao Chen3
1Department of Urology Surgery, Jinling Hospital, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, 210001, Jiangsu, China.
Heliyon
|June 17, 2024
概括
循环RNA circACTR2通过激活NF-κB通路促进了膀癌 (BCa) 的进展. 沉默circACTR2抑制BCa细胞的增殖,入侵和迁移,提供了一个潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 循环RNAs (circRNAs) 与瘤进展有关.
- 目前尚不清楚在膀癌 (BCa) 中,来自ARP2与actin相关蛋白2同源 (circACTR2) 的circRNA的具体作用.
- 了解circACTR2的功能对于BCa研究至关重要.
研究的目的:
- 为了研究circACTR2在膀癌中的生物学作用.
- 阐明在BCa.中circACTR2的功能背后的调节机制.
- 根据circACTR2.2确定BCa的潜在治疗点.
主要方法:
- 生物信息学分析被用来研究circACTR2.
- 使用RT-qPCR来量化circACTR2的表达.
- 细胞功能测试,包括功能丧失实验,评估了circACTR2对BCa细胞的影响.
主要成果:
- 发现circACTR2在BCa组织中受到上调.
- 沉默circACTR2显著抑制了BCa细胞的增殖,入侵和迁移.
- 从机制上讲,circACTR2作为miR-219a-2-3p的海绵,导致核因子kappa B激酶子单元β (IKBKB) 抑制剂的表达增加和NF-κB信号通路的激活.
结论:
- circACTR2通过miR-219a-2-3p/IKBKB/NF-κB轴促进了膀癌的进展.
- 抑制circACTR2代表了膀癌的潜在治疗策略.
- 这项研究为推动膀癌的分子机制提供了新的见解.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


